A positive clinical trial answers an essential question: Did the drug work?
It does not necessarily answer the question that will determine commercial success:
Why will a physician choose this drug for a particular patient?
That distinction is especially important in neurology.
Neurologists often have multiple treatment choices, established prescribing habits and patients who respond differently to therapy. A new drug can demonstrate statistical significance, receive regulatory approval and still enter the market without a compelling reason for physicians to change what they are already doing.
Commercial differentiation therefore needs to be considered while the drug is still being developed—not after the pivotal trial is complete.
Statistical Significance Is the Beginning
Clinical development is appropriately designed around regulatory requirements.
But the average treatment effect across a study population may not reveal where a drug has its greatest commercial value.
Two therapies can both improve the same clinical endpoint while producing very different outcomes for individual patients.
One may work particularly well in patients with greater disease severity. Another may offer better tolerability. A therapy may reduce seizures for many patients but produce seizure freedom in a smaller subset. Another may demonstrate an effect on cognition, function or behavior that becomes particularly important for a recognizable patient population.
Those differences can matter enormously to physicians and patients.
The commercial question is not simply whether the trial succeeded.
It is:
What happened to the patient that would make a physician choose this therapy over the alternatives?
Look Beyond the Average Patient
Neurological diseases are rarely uniform.
Disease severity, age, duration of illness, previous treatment, comorbidities and other clinical characteristics can influence both treatment response and physician decision-making.
That creates an opportunity during development.
If a company identifies patients who respond particularly well, the next question should be whether those patients share characteristics that can be recognized in clinical practice.
This does not necessarily require a biomarker or genetic test.
Sometimes the differentiating patient can be identified clinically.
Understanding that patient before Phase 3 can influence trial design, endpoints, evidence generation and eventually positioning.
Discovering the distinction after approval may be too late.
The Existing Treatment Pathway Matters
A new therapy does not enter an empty market.
It enters a treatment pathway that physicians already understand.
Some patients may be well controlled on inexpensive generic therapies. Others may cycle through multiple treatments because of inadequate efficacy or tolerability. Certain therapies may be reserved for later lines because of monitoring requirements, administration burden or payer restrictions.
A development program therefore needs to answer more than whether a drug works.
Where does it belong in the treatment pathway?
If the intended position is earlier treatment, what evidence will persuade physicians to change their current behavior?
If the therapy will initially be used after other treatments fail, is the remaining patient population large enough to support the commercial opportunity?
These are development questions as much as commercial questions.
Differentiation Must Be Visible in Clinical Practice
A scientific difference is not automatically a commercial difference.
Physicians need to recognize the benefit. Patients and caregivers need to experience it. Payers need evidence supporting its value.
That makes endpoint selection particularly important.
A statistically significant improvement on a clinical scale may support regulatory approval, but the commercial importance depends on whether that improvement translates into something meaningful in practice.
Depending on the disease, that might mean seizure freedom, preserved function, improved cognition, greater independence, fewer relapses, better tolerability or reduced treatment burden.
The strongest differentiation is often something a physician can see in the patient.
Build Commercial Questions Into Development
Before a neurology program enters expensive late-stage development, several questions should already be under consideration:
- Which patient benefits most?
- Can that patient be identified before treatment?
- What outcome would cause a physician to change treatment?
- Where should the therapy fit in the existing treatment pathway?
- How does it compare with therapies likely to be available at launch—not just those available today?
- What evidence will payers require to support that position?
Answering these questions does not replace good clinical development.
It helps ensure that clinical development is building a product physicians will have a reason to use.
A successful trial can get a neurology drug approved.
Commercial differentiation determines what happens after that.
About PharmaKonsult
PharmaKonsult advises biotechnology leaders on the clinical-development and commercialization decisions that shape an asset’s future commercial value. Learn more about our biotech commercialization consulting services.
